Patents Assigned to Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F.
S.p.A.
-
Publication number: 20170174657Abstract: The present invention relates to the 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta (GSK-3?) inhibitors and to their use in the treatment of GSK-3?-related disorders such as, for example, (i) insulin-resistance disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) cancerous disorders; (vi) inflammation, (vii) substance abuse disorders; (viii) epilepsies; and (ix) neuropathic pain.Type: ApplicationFiled: March 7, 2017Publication date: June 22, 2017Applicant: AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R. A.F. S.P.A.Inventors: Maria Alessandra ALISI, Nicola CAZZOLLA, Patrizia DRAGONE, Guido FURLOTTI, Caterina MAUGERI, Rosella OMBRATO, Francesca MANCINI
-
Publication number: 20170157121Abstract: The present invention relates to the 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta (GSK-3?) inhibitors and to their use in the treatment of GSK-3?-related disorders such as, for example, (i) insulin-resistance disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) cancerous disorders; (vi) inflammation, (vii) substance abuse disorders; (viii) epilepsies; and (ix) neuropathic pain.Type: ApplicationFiled: February 22, 2017Publication date: June 8, 2017Applicant: AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A.Inventors: Maria Alessandra ALISI, Nicola Cazzolla, Patrizia Dragone, Guido Furlotti, Caterina Maugeri, Rosella Ombrato, Francesca Mancini
-
Patent number: 9655906Abstract: Tricyclic indazole compound and its pharmaceutically acceptable salts of acid addition, use thereof, method and intermediates for preparing them, and a pharmaceutical composition containing them. The tricyclic indazole compound has the following general formula (I): in which R1, R2, L1, L2, X1, X2, X3, X4, X5, Y, W, m, and n have the meanings stated in the description.Type: GrantFiled: July 20, 2015Date of Patent: May 23, 2017Assignee: AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A.Inventors: Maria Alessandra Alisi, Nicola Cazzolla, Guido Furlotti, Beatrice Garrone, Gabriele Magaro, Giorgina Mangano
-
Publication number: 20170128442Abstract: A process of production of trazodone or trazodone hydrochloride that comprises: (a) preparing an organic phase comprising trazodone in at least one organic solvent; (b) preparing an aqueous phase comprising at least one basic compound; (c) mixing said aqueous phase with said organic phase; (d) heating at a temperature of at least 40° C. for at least 30 minutes; (e) recovering said trazodone; and, optionally, (f) treating said trazodone with hydrochloric acid to obtain trazodone hydrochloride. Trazodone or trazodone hydrochloride comprising less than 15 ppm of alkylating substances, and a pharmaceutical composition comprising said trazodone hydrochloride.Type: ApplicationFiled: January 25, 2017Publication date: May 11, 2017Applicant: AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A.Inventors: Marcello MARCHETTI, Tommaso IACOANGELI, Giovanni ClOTTOLI, Giuseppe BIONDI
-
Patent number: 9611249Abstract: The present invention relates to the 1H-indazole-3-carboxamide compounds having the following general formula (I) as glycogen synthase kinase 3 beta (GSK-3?) inhibitors and to their use in the treatment of GSK-3p-related disorders such as, for example, (i) insulin-resistance disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) cancerous disorders; (vi) inflammation, (vii) substance abuse disorders; (viii) epilepsies; and (ix) neuropathic pain.Type: GrantFiled: February 7, 2013Date of Patent: April 4, 2017Assignee: AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A.Inventors: Maria Alessandra Alisi, Nicola Cazzolla, Patrizia Dragone, Guido Furlotti, Caterina Maugeri, Rosella Ombrato, Francesca Mancini
-
Patent number: 9492542Abstract: The present invention relates to a pharmaceutical composition comprising a combination of 1-benzyl-3-hydroxymethylindazole derivative, a pressure lowering agent selected from ACE-inhibitors, renin inhibitors, ARBs and CCBs, and/or a cholesterol lowering agent selected from statin derivatives. The combination showed an additive and synergistic activity in reducing MCP-1 levels, thus significantly improving inflammatory response inhibition and consequently reducing complications occurring in patients suffering from inflammatory diseases.Type: GrantFiled: September 3, 2010Date of Patent: November 15, 2016Assignee: AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A.Inventors: Angelo Guglielmotti, Beatrice Garrone, Alessandro Ble', Giuseppe Biondi, Roberta Petrosemolo, Enrica Biondi, Iacopo Biondi
-
Publication number: 20160324853Abstract: A process of production of trazodone or trazodone hydrochloride that comprises: (a) preparing an organic phase comprising trazodone in at least one organic solvent; (b) preparing an aqueous phase comprising at least one basic compound; (c) mixing said aqueous phase with said organic phase; (d) heating at a temperature of at least 40° C. for at least 30 minutes; (e) recovering said trazodone; and optionally, (f) treating said trazodone with hydrochloric acid to obtain trazodone hydrochloride. Trazodone or trazodone hydrochloride comprising less than 15 ppm of alkylating substances, and a pharmaceutical composition comprising said trazodone hydrochloride.Type: ApplicationFiled: July 18, 2016Publication date: November 10, 2016Applicant: AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R. A.F. S.p.A.Inventors: Marcello MARCHETTI, Tommaso IACOANGELI, Giovanni Battista CIOTTOLI, Giuseppe BIONDI
-
Patent number: 9416116Abstract: The present invention relates to a method of preparation of metaxalone comprising reaction of triglycidyl isocyanurate (TGIC) with m-xylenol, characterized in that said reaction is carried out in a solvent mixture comprising an aprotic polar solvent with dielectric constant greater than or equal to 30 and at least one other solvent selected from the group comprising apolar solvents and aprotic polar solvents with dielectric constant below 30 said solvent mixture comprising from 5 to 40 wt. % of said first solvent and from 95 to 60 wt. % of said second solvent, adding the TGIC at a temperature between 30° C. and 50° C., and after adding the TGIC, raising the temperature of the reaction solution to a value between 80° C. and 180° C. in a time between 120 and 180 minutes at a rate of increase not greater that 1.25° C. per minute. The invention also relates to a metaxalone with a reduced content of impurities derived from incomplete reactions and/or side reactions of the method of production.Type: GrantFiled: June 17, 2015Date of Patent: August 16, 2016Assignee: AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A.Inventors: Tommaso Iacoangeli, Mario Chiavarini, Antonello Fazio, Marcello Marchetti, Giovanni Battista Ciottoli
-
Publication number: 20160113926Abstract: A process of production of trazodone or trazodone hydrochloride that comprises: (a) preparing an organic phase comprising trazodone in at least one organic solvent; (b) preparing an aqueous phase comprising at least one basic compound; (c) mixing said aqueous phase with said organic phase; (d) heating at a temperature of at least 40° C. for at least 30 minutes; (e) recovering said trazodone; and, optionally, (f) treating said trazodone with hydrochloric acid to obtain trazodone hydrochloride. Trazodone or trazodone hydrochloride comprising less than 15 ppm of alkylating substances, and a pharmaceutical composition comprising said trazodone hydrochloride.Type: ApplicationFiled: January 4, 2016Publication date: April 28, 2016Applicant: AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A.Inventors: Marcello MARCHETTI, Tommaso IACOANGELI, Giovanni Battista CIOTTOLI, Giuseppe BIONDI
-
Publication number: 20160102056Abstract: The present invention relates to novel benzoyl derivatives of 3-aminocarbazole, to a pharmaceutical composition containing them, to a method for preparing them and to the use of such compounds for the production of a drug that is useful in the treatment or prevention of disturbances associated with the production of prostaglandin E2 (PGE2), for instance inflammatory processes, pain, fever, tumours, Alzheimer's disease and atherosclerosis.Type: ApplicationFiled: December 15, 2015Publication date: April 14, 2016Applicant: AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A.Inventors: Maria Alessandra Alisi, Nicola Cazzolla, Isabella Coletta, Patrizia Dragone, Guido Furlotti, Barbara Garofalo, Angelo Guglielmotti, Giorgina Mangano, Caterina Maugeri
-
Publication number: 20160068615Abstract: The present invention relates to glycogen-based polymers and the use thereof for enhancing the solubility in water of lipophilic compounds, to complexes of the said glycogen-based polymers with lipophilic compounds and the use thereof for administering lipophilic compounds, and to pharmaceutical, nutraceutical, and cosmetic compositions comprising the said complexes.Type: ApplicationFiled: March 31, 2014Publication date: March 10, 2016Applicant: AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A. F. S.p.A.Inventors: Vincenzo RUSSO, Elisa LIBERATI, Serena TONGIANI
-
Publication number: 20160045485Abstract: The present invention relates to the new use of 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta (GSK-3?) inhibitors and to their use in the treatment of GSK-3?-related disorders such as, for example, (i) insulin-resistance disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) cancerous disorders; (vi) inflammation, (vii) substance abuse disorders; and (viii) epilepsies.Type: ApplicationFiled: August 13, 2015Publication date: February 18, 2016Applicant: Aziende Chimiche Riunite Angelini Francesco A.C.R. A.F. S.P.A.Inventors: Maria Alessandra ALISI, Nicola Cazzolla, Barbara Garofalo, Guido Furlotti, Gabriele Magaro', Rosella Ombrato, Francesca Mancini
-
Patent number: 9255073Abstract: The present invention relates to novel 1-benzyl-3-hydroxymethylindazole derivatives according to formula (I) described in the claims, and to a pharmaceutical composition comprising them, together with a pharmaceutically acceptable vehicle. In addition, the present invention relates to the use of 1-benzyl-3-hydroxymethylindazole derivatives for the preparation of a pharmaceutical composition that is active in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40, and to their use in a method for treating or preventing diseases based on the expression of MCP-1, CX3CR1 and p40.Type: GrantFiled: May 21, 2013Date of Patent: February 9, 2016Assignee: AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A.Inventors: Angelo Guglielmotti, Guido Furlotti, Giorgina Mangano, Nicola Cazzolla
-
Patent number: 9249097Abstract: The present invention relates to novel benzoyl derivatives of 3-aminocarbazole, to a pharmaceutical composition containing them, to a method for preparing them and to the use of such compounds for the production of a drug that is useful in the treatment or prevention of disturbances associated with the production of prostaglandin E2 (PGE2), for instance inflammatory processes, pain, fever, tumours, Alzheimer's disease and atherosclerosis.Type: GrantFiled: December 17, 2013Date of Patent: February 2, 2016Assignee: AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A.Inventors: Maria Alessandra Alisi, Nicola Cazzolla, Isabella Coletta, Patrizia Dragone, Guido Furlotti, Barbara Garofalo, Angelo Guglielmotti, Giorgina Mangano, Caterina Maugeri
-
Publication number: 20150320763Abstract: Tricyclic indazole compound and its pharmaceutically acceptable salts of acid addition, use thereof, method and intermediates for preparing them, and a pharmaceutical composition containing them. The tricyclic indazole compound has the following general formula (I): in which R1, R2, L1, L2, X1, X2, X3, X4, X5, Y, W, m, and n have the meanings stated in the description.Type: ApplicationFiled: July 20, 2015Publication date: November 12, 2015Applicant: AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F S.p.A.Inventors: Maria Alessandra ALISI, Nicola CAZZOLLA, Guido FURLOTTI, Beatrice GARRONE, Gabriele MAGARO, Giorgina MANGANO
-
Publication number: 20150297589Abstract: A process of production of trazodone or trazodone hydrochloride that comprises: (a) preparing an organic phase comprising trazodone in at least one organic solvent; (b) preparing an aqueous phase comprising at least one basic compound; (c) mixing said aqueous phase with said organic phase; (d) heating at a temperature of at least 40° C. for at least 30 minutes; (e) recovering said trazodone; and, optionally, (f) treating said trazodone with hydrochloric acid to obtain trazodone hydrochloride. Trazodone or trazodone hydrochloride comprising less than 15 ppm of alkylating substances, and a pharmaceutical composition comprising said trazodone hydrochloride.Type: ApplicationFiled: June 29, 2015Publication date: October 22, 2015Applicant: AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R. A.F. S.p.A.Inventors: Marcello MARCHETTI, Tommaso IACOANGELI, Giovanni Battista CIOTTOLI, Giuseppe BIONDI
-
Patent number: 9163013Abstract: 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors. The present invention relates to the 1H-indazole-3-carboxamide compounds for use as glycogen synthase kinase 3 beta (GSK-3?) inhibitors and to their use in the treatment of GSK-3?-related disorders such as, for example, (i) insulin-resistance disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) cancerous disorders; (vi) inflammation, (vii) substance abuse disorders; and (viii) epilepsies.Type: GrantFiled: February 8, 2013Date of Patent: October 20, 2015Assignee: AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A.Inventors: Maria Alessandra Alisi, Nicola Cazzolla, Barbara Garofalo, Guido Furlotti, Gabriele Magaro′, Rosella Ombrato, Francesca Mancini
-
Publication number: 20150284345Abstract: The present invention relates to a method of preparation of metaxalone comprising reaction of triglycidyl isocyanurate (TGIC) with m-xylenol, characterized in that said reaction is carried out in a solvent mixture comprising an aprotic polar solvent with dielectric constant greater than or equal to 30 and at least one other solvent selected from the group comprising apolar solvents and aprotic polar solvents with dielectric constant below 30 said solvent mixture comprising from 5 to 40 wt. % of said first solvent and from 95 to 60 wt. % of said second solvent, adding the TGIC at a temperature between 30° C. and 50° C., and after adding the TGIC, raising the temperature of the reaction solution to a value between 80° C. and 180° C. in a time between 120 and 180 minutes at a rate of increase not greater that 1.25° C. per minute. The invention also relates to a metaxalone with a reduced content of impurities derived from incomplete reactions and/or side reactions of the method of production.Type: ApplicationFiled: June 17, 2015Publication date: October 8, 2015Applicant: AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A.Inventors: Tommaso IACOANGELI, Mario CHIAVARINI, Antonello FAZIO, Marcello MARCHETTI, Giovani CIOTTOLI
-
Patent number: 9125823Abstract: The present invention relates to a controlled release pharmaceutical or food formulation comprising at least one active pharmaceutical or food ingredient dispersed in a mixture of a glycogen with a polysaccharide, and the process for its preparation. The invention also relates to a slow release system represented by a mixture of a glycogen with a polysaccharide, and its use for the preparation of slow release pharmaceutical or food formulations.Type: GrantFiled: January 8, 2010Date of Patent: September 8, 2015Assignee: AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A.Inventors: Stefano Selva, Leonardo Marchitto, Giovanni Battista Ciottoli, Lorella Ragni, Vincenzo Russo, Elisa Liberati
-
Patent number: 9120801Abstract: Tricyclic indazole compound and its pharmaceutically acceptable salts of acid addition, use thereof, method and intermediates for preparing them, and a pharmaceutical composition containing them. The tricyclic indazole compound has the following general Formula (I): in which R1, R2, L1, L2, X1, X2, X3, X4, X5, Y, W, m, and n have the meanings stated in the description.Type: GrantFiled: March 4, 2011Date of Patent: September 1, 2015Assignee: AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A.Inventors: Maria Alessandra Alisi, Nicola Cazzolla, Guido Furlotti, Beatrice Garrone, Gabriele Magaro', Giorgina Mangano